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ABSTRACT 
  
VEGF (vascular endothelial growth factor) is a growth factor responsible for 
angiogenesis, which is the development of new blood vessels from preexisting ones. 
Oxygen and nutrients are supplied to tumors by blood vessels and tumor growth is greatly 
limited without angiogenic capabilities.  Targeting VEGF is a promising strategy for 
cancer treatment and preventing metastasis. The focus of this project is to inhibit VEGF-
VEGFR-2 (VEGF receptor 2) interaction high affinity by producing anti-peptide 
antibodies that will compete with VEGF for the binding region of VEGFR-2. VEGFR-2 
has been shown to bind VEGF and stimulate angiogenesis, thereby resulting in increased 
tumor growth and metastasis. The hypothesis to be tested is whether these anti-peptide 
antibodies are able to recognize VEGFR-2 by specifically binding to the protein. The 
peptides were synthesized by solid phase peptide synthesis and binding was tested against 
antibodies produced in outbred rabbits that had been immunized with the peptide vaccine. 
Antibodies to the natural sequence (VEGF 102-122), its cyclic sequence (VEGF P3), and 
its retro-inverso sequence (VEGF P4) were tested against the peptides in both simple and 
competitive ELISA. In the case of immunization, the VEGF B-cell epitopes were co-
linearly synthesized with the promiscuous T-helper epitope MVF, which is the measles 
virus fusion protein. The B-cell and T-cell epitopes were linked by a flexible four-residue 
turn (GPSL) linker which allows for each epitope to fold independently. Linked with the 
B-cell epitopes were MVF-VEGF 102-122, MVF-VEGF P3, and MVF-VEGF P4. The 
synthesized peptide vaccines were immunogenic and elicited antibody production by the 
     
 3 
immune system, which successfully bind and recognize the peptide and the natural VEGF 
protein. The antibodies should be able to prevent growth of tumors dependent on VEGF 
and angiogenesis. Results from the competitive ELISA showed that VEGF peptide 
mimics were able to prevent the antibodies from binding the VEGF protein. These highly 
specific anti-peptide antibodies should have therapeutic potential in most cancers that are 
dependent on angiogenesis. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1 Cancer Today 
Cancer kills more than 562,000 Americans every year. It is responsible for one out of 
every four deaths in the United States [1]. It is the second leading cause of death in the 
United States following heart disease (612,000 deaths). In 2007, 23.2% of all deaths in 
the United States were due to cancer (Table 1.1). Although cancer is prevalent with over 
1.5 million new cases diagnosed each year, survival rates have increased significantly in 
the past 25 years (Table 1.2). The data suggest that current treatments are able to lower 
mortality amongst the patients that have been diagnosed with cancer. The available 
options currently include surgery, radiation therapy, and chemotherapy. These all have 
debilitating side effects and most of the chemotherapeutic agents have unacceptable 
safety profiles and are also expensive. The physical and financial burden from cancer is 
immense with total cancer costs exceeded $228 billion dollars in 2008.  
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1.2 Current Cancer Treatment Methods 
Cancer is the uncontrolled growth of cells that continually divide with no regulation. 
Treatments for cancer include surgical removal, controlling or killing the cancerous cells. 
Chemotherapy, surgical resection, and radiation therapy are the most common options for 
cancer treatment. 
Chemotherapy 
Chemotherapy is the use of strong drugs to treat cancer. With more than 100 variations of 
chemotherapeutic drugs available, doctors are able to select the one that would best treat 
the specific condition. This treatment method is effective for slowing the cancer growth 
and killing cancer cells that may spread to other areas. Oftentimes multiple 
chemotherapeutic drugs are used in combination to better combat cancer, which is called 
combination chemotherapy. Although chemotherapy is effective in killing cancerous cells 
it also kills normal cells, which is a major side effect for the treatment method. Hair loss, 
bone marrow density changes, memory and emotional changes are experienced by 
patients undergoing chemotherapy. 
Radiation Therapy 
Radiation therapy is the use of high-energy particles, such as x-rays, gamma rays, 
electron beams, or protons, to destroy or damage cancer cells. It is used with other 
treatments or drugs known as radiosensitizers, which make the cancer cells more 
sensitive to the radiation. The therapy works by using concentrated radiation on the 
cancer cells to destroy their DNA and prevent growth, division, and spreading by the 
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cells. Normal cells in the area may also be affected, which is a side effect. Other side 
effects include radiation-induced nausea, skin changes, fatigue, and low blood counts. 
Surgery 
Surgery is a technique used to both diagnose and treat cancer. Cancer biopsies are tissue 
sections removed to screen for cancerous cells. Surgery is also used to remove tumors 
confined to one area. Although it is difficult to remove cancer tumors completely, the 
surgery in combination with other treatments can reduce the cancer greatly and increase 
survival rate. Side effects of surgery include excessive bleeding, complications during 
surgery including infection, pain, and damage to organs.  
 
1.3 Function of VEGF 
 
VEGF, also called vascular permeability factor (VPF), is a pro-angiogenic factor and its 
actions are mediated through binding to two receptor tyrosine kinases, VEGFR-1 and 
VEGFR-2. By activating these receptors with VEGF, phosphorylation of proteins 
responsible for signal transduction for cellular regulation occurs [6]. VEGF plays a key 
role in development of the vascular network in vasculogenesis (embryogenesis or 
formation of new vessels) and angiogenesis (formation of new blood vessels from 
existing vessels) [7]. The VEGF protein family consists of VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and placental growth factor. Of these unique proteins, VEGF-A binds to 
VEGFR-1 and -2, which are involved in triggering angiogenesis, making it the most 
studied of the VEGF family [3].  
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1.4 Tumors and Angiogenesis 
A major focus of the lab is the prevention of angiogenesis. Angiogenesis is the growth of 
new blood vessels from pre-existing vessels. The importance of inhibiting angiogenesis is 
seen in tumor suppression and cancer treatment. The tumors in multiple cancers have 
been shown to be dependant on tumor vasculature [2]. The process of angiogenesis is 
four fold: the degradation of the basal lamina that covers existing blood vessels, 
migration toward an angiogenic signal, proliferation and the eventual formation of new 
tubular structures [3].  Although increased angiogenesis has potential health benefits such 
as in a stroke or heart-attack patient, the proliferation of tumors due to angiogenic factors 
is a cause for concern. The tumors are able to maintain growth with sufficient oxygen, 
which is only possible with new vessels. With oxygen and essential nutrients being 
supplied, tumor growth is likely to occur. This process is driven by production of pro-
angiogenic factors that override the effect of inhibitory angiogenic factors.  One of these 
activators is VEGF (vascular endothelial growth factor) [4].  Because of noted 
dependence of tumor growth on angiogenesis, the idea of combining anti-angiogenic 
therapeutic drugs along with conventional cancer therapies has become the treatment 
option for most cancers today [4, 5]. 
 
1.5 Anti-Angiogenic Agents as Therapy 
 Chemotherapy has been the basis for cancer treatment for decades. This has 
presented considerable toxicities that limit the amount of treatment and cause differing 
adverse side effects in the patient as well as developments of immunogenicity to 
treatment. The development of specific agents that directly target the malignant cell or 
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tumor-supporting cells is being studied [6]. With the developing research on the role of 
angiogenesis and the dependence of growth on vascular supply, research targeting tumor 
angiogenesis has been a major focus in the past decade. Over-expression of VEGF has 
been seen in the majority of cancers, including colorectal, liver, lung, thyroid, breast, 
gastrointestinal tract, kidney, and bladder cancers as well as ovary and uterine cervix, 
among others [6]. One way to interrupt angiogenesis, directly or indirectly, depends 
primarily on interfering with the VEGF-dependent pathway, especially the VEGF: 
VEGFR-2 signaling.  
Because of the dependence of tumor growth and metastasis on angiogenesis, anti-
angiogenic therapies are being studied as alternatives in cancer treatment.  Theoretically, 
starving a tumor of nutrients required for growth is possible by inhibiting the growth of 
new blood vessels to that tumor. A noted regulator of angiogenesis, which has led to 
tumor growth is seen in VEGF. As seen in preclinical and clinical studies, VEGF has a 
direct effect on tumor growth. The preclinical models showed greater growth and 
metastatic potential in human tumor xenografts, while clinical trials have shown early 
stages of breast cancer with associated VEGF expression have greater metastatic 
potential. The large impact VEGF and its receptors have had on angiogenesis has led to 
the focus of anti-angiogenic therapy by blocking these signals [2].  An example is 
Bevacizumab (Avastin®), a humanized monoclonal antibody developed by Genentech 
that was granted FDA approval as a drug to be used in colorectal cancer in 2005 and 
recently in breast cancer in 2008 [8,9]. It is so far the most successful anti-angiogenic 
inhibitor clinically, however some patients have demonstrated complications such as 
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hypertension, which may be due to VEGF and its role in the vascular system. Also cases 
of cardiotoxicity and resistance have been reported. 
 VEGFR-2 has demonstrated a highly active tyrosine kinase signal, which triggers 
angiogenesis. Inhibiting the kinase ATP binding sites is a greatly studied approach to 
prevent angiogenesis. The drugs are easily administered by oral doses. An issue in this 
treatment is seen when the kinase develops resistance by mutating [10,11]. Sunitinib 
(Sutent®), is an FDA approved tyrosine kinase inhibitor that targets VEGFR-2 and was 
approved in 2006 for first-line therapy for advanced renal cancer and gastrointestinal 
stromal tumor (GIST) [12]. 
 
1.6 VEGF and its receptors 
The mechanism for VEGF receptor signaling comprises of receptor activation, by binding 
VEGF activation of the tyrosine kinase to phosphorylate proteins, and creation of 
docking sites for signaling proteins from several pathways. Although VEGF binds to a 
variety of cell surface proteins, the highest affinity is to VEGFR-1 and VEGFR-2, 
transmembrane receptor tyrosine kinases. These receptor proteins are expressed mainly in 
the endothelial cells of the vascular endothelium. Although VEGF binds to VEGFR-1 
with higher affinity, the receptor activation is weaker for unknown reasons [3]. As a 
result of the weak receptor, it was thought that VEGFR-1 was simply a decoy to decrease 
VEGFR-2 signaling, but recent studies have shown the importance of VEGF-1 signaling 
in the activation of migration in the monocytes/macrophages, recruiting them to the 
tumor microenvironment [13, 14, 15]. It has been found that VEGF and VEGFR-2 
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interaction is required in order to trigger angiogenesis and the blocking of this interaction 
is a viable strategy for developing anti-angiogenic drugs [13, 16-21].  
 
1.7 Peptides and Retro-Inverso Peptides 
Peptides are small chains of amino acids that mimic parts of an entire protein. The site of 
interest that the peptide mimics is generally biologically active and accessible. Synthetic 
peptides are developed usually by using a structure-based design of the binding or active 
site that is trying to be inhibited (Figure 1.2). These peptides are chemically synthesized 
to fit the molecules as precisely as possible. The key factor when synthesizing peptides is 
designing them while maintaining conformational space and orientation of the bioactive 
surface while retaining sufficient flexibility to bind cooperatively with a given receptor.  
The therapeutic benefits of peptides include being water soluble, non-immunogenic, and 
able to easily cross tissue barriers. The drawback of using peptides as a therapeutic agent 
is that they are easily degraded in vivo by proteases, thereby requiring repeated 
treatments. In order to prevent degradation by proteases, retro-inverso modification is 
used. Retro-inverso modification is the reverse of the peptide backbone by inverting the 
amino acid sequence and chirality by utilizing D-amino acids (Figure 1.3). The retro-
inverso peptides have the same orientation of the side chains, which appear 
topographically equivalent to the original peptide.  Natural amino acids, easily 
recognized by the body are L-amino acids so the use of D-amino acids generally will 
avoid being degraded by proteases and make their use in vivo a better option (Table 1.3) 
[3].  
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1.8 Vaccine Strategy using Peptides 
 The role of antibodies is to specifically recognize and bind foreign antigens. B-
cells produce antibodies and protection against repeated exposure against the antigens 
and this is seen because B-cell memory is activated when exposed again. The ability to 
produce antibodies outside the body and introduce them as therapeutic agents, offers a 
new alternative. An important component of administering the therapeutic antibodies is 
them not being recognized as a foreign antigen to the body when administered [26, 27]. A 
mechanism of action by these antibodies is the interaction protein-protein interaction by 
specifically targeting the receptor site where the binding occurs [28].  
 High affinity antibodies need to be able to bind to epitopes that contain essential 
residues for their interaction. The epitopes need to be designed, taking into consideration 
that the binding area of a protein is the result of a structural arrangement of residues. 
Peptides can also combine both B- and T-cell epitopes constructed in a collinear fashion. 
Using a universal T-helper epitope from measles virus fusion protein (MVF), the 
immunogenicity of designed peptides is increase [29, 30]. Because VEGF 102-122, 
VEGF P3, and VEGF P4 are all B-cell epitopes, a MVF sequence was linked to them to 
evaluate the potential to generate antibodies that would recognize and specifically bind 
VEGF. These anti-VEGF peptide mimic antibodies should show inhibitory effects due to 
binding to VEGF and the blockage of the VEGF-VEGFR-2 interaction.    
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Table 1.1 Number of cancer related deaths in 2007 in the United States. VEGF is over 
expressed in many of these cancers. 
     
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2 Trends in survival rate of diagnosed cancers between 1975 and 2005.  
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Figure 1.1 Angiogenesis dependent tumor growth and metastasis. Tumor cells up-
regulate pro-angiogenic factors (VEGF) that promote the formation of new blood vessels 
to supply tumors with nutrients and oxygen needed to grow. After certain growth, the 
tumors metastasize and use the vessels to migrate to new sites throughout the body. 
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Table 1.3 Amino acid sequences and molecular weight of VEGF peptide mimics. 
Sequences of amino acids are represented from N to C-terminal. #AA represents number 
of amino acids in each peptide and Mol. Wt. represents the molecular weight of peptides. 
 
peptides: 
Peptide 
Sequence 
#AA Mol. Wt. 
VEGF 102-122        (102)-76-ITMQ IMRIKPHQGQHIG EMSF-96-(122) 21 2481 
VEGF-P3(CYC)   76–ITMQ-79-C-92-GIHQGQHPKIRMI-80-C-EMSF-96 23 2724 
VEGF-P4(CYC)  76-ITMQ-79-C-92-IMRIKPHQGQHIG-80-C-EMSF-96 23 2724 
(Da) 
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A.     B. 
 
 
 
Figure 1.2: Schematic representation of the VEGF peptide mimic design. (A) VEGF 
sequence 102-122 (76-96) from crystal structure with labeled residues. (B) Peptide mimic 
VEGF-P3(CYC). In black is shown the VEGF-P3(CYC) peptide sequence with labeled 
residues; arrows show anti-parallel β-sheet orientation based on the crystal structure as 
represented in (A) with the same colors. 
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A C B 
Figure 1.3: Schematic representation of the effects of retro-inverso 
peptides . Natural orientation of parent L-amino acid peptide (A). Reversed 
side chain orientation in D-amino acid peptide (B). Retro-inverso peptide 
with restored side chain orientation (C). 
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CHAPTER 2 
METHODS AND MATERIALS 
 
2.1 Peptide Synthesis 
 Peptides were synthesized on Milligen/Biosearch 9600 solid-phase peptide 
syntesizer using Fmoc/t-But chemistry. VEGF 102-122 was synthesized using preloaded 
Fmoc-Phe-CLEAR acid resin while VEGF-P3 was synthesized using CLEAR amide 
resin (Pepides International, Louisville, KY). VEGF-P3 was acetylated on resin, using 
acetyl imddazole reagent following protocol. All peptides were cleaved from the resin 
using cleavage reagent B (Trifluoroacteic acid:Phenol:Water:Triisopropyl silane 
90:4:4:2) and crude peptides were purified on preparative RP-HPLC (Reverse Phase-
High Pressure Liquid Chromatography) using Vydac C-4 column and acetonitrile-water 
(0.1 % TFA) gradient system. All fractions were analyzed on analytical RP-HPLC and 
characterized by MALDI (Matrix Assisted Laser Desorption Ionization mass 
spectroscopy) at CCIC (Campus Chemical Instrumentation Center, The Ohio State 
University, Columbus, OH). RP-HPLC pure peptide VEGF-P3 containing two Cysteine 
residues was synthesized retro-inverso to form VEGF-P4 (RI-VEGF-P3). Amino acid 
sequences and molecular weight of VEGF peptide mimics as determined by MS are 
shown in Table 1.1.  
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2.2 Rabbit Immunization 
New Zealand white rabbits were immunized with 1 mg of peptide dissolved in 
distilled water emulsified (1:1) in Montanide ISA720 vehicle (Sepic) with 100 µg of N-
acetylglucosamine-2yl-acetyl-1-alanyl-d-isoglutamine (nor-MDP). Rabbits were boosted 
with the respective doses at three week intervals. Rabbit blood was collected via the 
central auricular artery and sera were tested for antibody titers. Anti-peptide antibodies 
were purified by affinity chromatography using a Protein A/G column (Thermo Fisher 
Scientific Inc, Rockford, IL) from high-titer  sera. 
 
 
2.3 Antibody Purification 
 Sear, 3 mL was diluted a minimum of 1:1 using de-gassed Binding Buffer. The 
sodium azide storage solution was allowed to run through the column. Twice, Binding 
Buffer was equilibrated running 10 mL through and the pH was checked to be 
approximately 8.0. The diluted sample was allowed to run before washing the column 
using 20 mL of Binding Buffer. The antibodies from the column were eluted by using 10 
mL of Elution Buffer. Ten 1 mL fractions were collected in pre-labeled eppendorf tubes 
after 10 mL of buffer were added. The column was regenerated by running 8 mL of 
Elution Buffer through it. The samples of eluted antibodies were read at 280 nm using a 
Spectrophotometer. The samples that have an absorbance reading of 0.3 or higher are 
pooled and spun down in a filter centrifugation tube at 2000 rpm for 30 min. The samples 
were topped with 4 mL of 0.1% Tween 20/PBS and after 2 washes the concentrated 
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antibody was transferred to a labeled eppendorf tube where using a Coomassie Plus 
Protein Assay, the concentration of the antibody were determined. 
 
2.3 VEGF Direct ELISA 
 Plates were coated overnight at 4 °C with 100 uL of 2 ug/mL rhVEGF (R&D 
Systems, Minneapolis, MN), washed four times with 0.1 % Tween 20/PBS, and blocked 
with 200 uL of 1% BSA/PBS for 1 h at room temperature. Plates were washed four times 
with 0.1% Tween 20/PBS. Anti-peptide sera were serially diluted down the plate to 
cerate several dilutions and incubated 2 h at room temperature. Plates were washed four 
times with 0.1 % Tween 20/PBS, a 1/500 dilution of goat-anti-rabbit IgG HRP was added 
and incubated 1 h. Detection was done coating the plate with ABTS substrate in the dark 
for 10 minutes before absorbance reading took place at 415 nm.  
 
2.4 Competitive ELISA 
 Plates were coated overnight at 4 °C with 100 uL of 2 ug/mL rhVEGF (R&D 
Systems, Minneapolis, MN), washed four times with 0.1 % Tween 20/PBS, and blocked 
with 200 uL of 1% BSA/PBS for 1 h at room temperature. Plates were washed four times 
with 0.1% Tween 20/PBS. 50 uL of PBT/HS were added to rows B through H and 100 
uL of 40uM of soluble inhibitor added to top row where it was serially diluted down the 
column except last wells. Sera dilutions based on direct ELISA titer where dilution curve 
is linear. 50uL of sera (antibody) dilution added to each well. Plates incubated at room 
temperature for two hours. Plates were washed four times with 0.1 % Tween 20/PBS, a 
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1/500 dilution of goat-anti-rabbit IgG HRP was added and incubated 1 h. Detection was 
using ABTS substrate was read at 415 nm.  
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CHAPTER 3 
RESULTS 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Antibody responses elicited by MVF-VEGF-P3 peptide vaccines in 
outbred rabbits. Two rabbits per group were each immunized with the MVF-VEGF-
P3(CYC) peptide.  Blood was drawn weekly, and sera surveyed for peptide-specific 
antibody by ELISA.  The results of each individual rabbit are shown.  Titers are defined 
as the reciprocal of the highest serum dilution with an absorbance of 0.2 or greater after 
subtracting the background. 4y+3w indicates the antibody titer in blood drawn three 
weeks after the fourth immunization [1]. 
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Figure 3.2 Antibody responses elicited by MVF-VEGF-P4 peptide vaccines in 
outbred rabbits. Two rabbits per group were each immunized with the MVF-VEGF-P3 
peptide.  Blood was drawn weekly, and sera surveyed for peptide-specific antibody by 
ELISA.  The results of each individual rabbit are shown.  Titers are defined as the 
reciprocal of the highest serum dilution with an absorbance of 0.2 or greater after 
subtracting the background. 4y+3w indicates the antibody titer in blood drawn three 
weeks after the fourth immunization [1]. 
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Figure 3.3 Anti-MVF-VEGF 102-122 competitive inhibition ELISA.  Plates were 
coated with MVF-VEGF 102-122 peptide and anti-MVF-VEGF 102-122 binding was 
analyzed directly (A) or in competition assay (B) where VEGF peptide mimics were used 
as inhibitor. 
Competitive ELISA MVF 102-dilution 1/32000
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1052.51.250.6250.31250
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Figure 3.3   shows   the direct (A) and   competitive ELISA (B) between MVF-VEGF 
102-122   and   anti-MVF-VEGF 102-122 antibodies, which were produced   after   New 
Zealand  white  rabbits  were immunized  three  times at three-week intervals. The  bleed, 
4y+1w (one week after the  fourth immunization)   was found  to  have   the  highest  titer 
readings.  The purified antibodies  from the 4y+1w bleed  were then added to  the 96-well 
plates that  had   been   coated  with  MVF-VEGF 102-122.  The competitive   ELISA    
also  used  different   peptides   as   inhibitors to prevent binding   between   MVF-VEGF 
102-122   and   its  antibodies. As  is  expected, the irrelevant   peptide (IRR) showed   no 
ability to inhibit  MVF-VEGF 102-122 binding   to its antibody. The peptide has  an 
amino acid sequence that   does   not correspond to  the  VEGF-VEGFR-2 sequence  and   
therefore it   should  show  no  inhibition of   binding  .MVF-VEGF P3, VEGF 102-122, 
and MVF-VEGF 102-122 had different binding inhibiting abilities. 
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Figure 3.4 Anti-MVF-VEGF P3 competitive inhibition ELISA.  Plates were coated 
with MVF-VEGF P3 peptide and anti-MVF-VEGF P3 binding was analyzed directly (A) 
or in competition assay (B) where VEGF peptide mimics were used as inhibitors. 
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Figure 3.4 shows the direct (A) and competitive ELISA (B) between MVF-VEGF P3 and 
anti-MVF-VEGF P3 antibodies, which were produced after New Zealand white rabbits 
were immunized three times at three week intervals. The bleed, 4y+3w (three weeks after 
the fourth immunization) was found to have the highest titer readings (Figure 3.1). The 
purified antibodies from the 4y+3w bleed were then added to the 96-well plates that had 
been coated with MVF-VEGF P3. The competitive ELISA also used different peptides as 
inhibitors to prevent binding between MVF-VEGF P3 to its antibody. The irrelevant 
peptide (IRR) showed no ability to inhibit MVF-VEGF P3 binding to its antibody. MVF-
VEGF P3, VEGF 102-122, and MVF-VEGF 102-122 all had differing biding inhibition 
abilities with VEGF P3 showing the most inhibition.                                     
     
 33 
Anti MVF P4 Direct ELISA
0
0.2
0.4
0.6
0.8
1
1.2
80
00
16
00
0
32
00
0
64
00
0
12
80
00
25
60
00
51
20
00
10
24
00
0
1/dilution
ab
so
rb
an
ce
 (
4
1
5
n
m
)
anti MVF P4
Pre-sera
A  
 
 
 
 
 
 
 
 
 
B 
 
 
 
Figure 3.5 Anti-MVF-VEGF P4 competitive inhibition ELISA.  Plates were coated 
with MVF-VEGF P4 peptide and anti-MVF-VEGF P4 binding was analyzed directly (A) 
or in competition assay (B) where VEGF peptide mimics were used as inhibitors.
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Figure 3.5 shows the direct (A) and competitive ELISA (B) between MVF-VEGF P4 and 
anti-MVF-VEGF P4 antibodies, which were produced after New Zealand white rabbits 
were immunized three times at three-week intervals. The bleed, 6y+3w (three weeks after 
the sixth immunization) was found to have the highest titer readings (Figure 3.2). The 
purified antibodies from the 6y+3w bleed were then added to the 96-well plates that had 
been coated with MVF-VEGF P4. The competitive ELISA also used different peptides as 
inhibitors to prevent binding between MVF-VEGF P4 and its antibodies. The irrelevant 
peptide (IRR) showed no ability to inhibit MVF-VEGF P4 binding to its antibody. MVF-
VEGF P4, VEGF P4, and MVF-VEGF 102-122 had differing binding inhibiting abilities 
with VEGF P4 having the greatest inhibiting abilities. 
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Figure 3.6 Anti-VEGF 102-122 competitive inhibition ELISA.  Plates were coated 
with VEGF 102-122 peptide and anti-VEGF 102-122 binding was analyzed directly (A) 
or in competition assay (B) where VEGF peptide mimics were used as inhibitors.
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Figure 3.6 shows the direct (A) and competitive ELISA (B) between VEGF 102-122 and 
anti- VEGF 102-122 antibodies, which were produced after New Zealand white rabbits 
were immunized three times at three week intervals. The bleed, 4y+1w (one week after 
the fourth immunization) was found to have the highest titer readings. The purified 
antibodies from the 4y+1w bleed were then added to the 96-well plates that had been 
coated with VEGF 102-122. The competitive ELISA also used different peptides as 
inhibitors to prevent binding between VEGF 102-122 and its antibodies. As is expected, 
the irrelevant peptide (IRR) showed no ability to inhibit VEGF 102-122 binding to its 
antibody. The peptide has an amino acid sequence that does not correspond to the VEGF-
VEGFR-2 sequence and therefore it should show no inhibition. MVF-VEGF P4, VEGF 
102-122, and MVF-VEGF 102-122 had inconsistent inhibiting abilities.
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Figure 3.7 Anti-VEGF P3 competitive inhibition ELISA.  Plates were coated with 
VEGF P3 peptide and anti -VEGF P3 binding was analyzed directly (A) or in 
competition assay (B) where VEGF peptide mimics were used as inhibitors.
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Figure 3.7 shows the direct (A) and competitive ELISA (B) between VEGF P3 and anti-
VEGF P3 antibodies, which were produced after New Zealand white rabbits were 
immunized three times at three-week intervals. The bleed, 4y+3w (three weeks after the 
fourth immunization) was found to have the highest titer readings (Figure 3.7). The 
purified antibodies from the 4y+3w bleed were then added to the 96-well plates that had 
been coated with VEGF P3. The competitive ELISA also used different peptides as 
inhibitors to prevent binding between VEGF P3 and its antibodies. As is expected, the 
irrelevant peptide (IRR) showed no ability to inhibit VEGF P3 to its antibody. The 
peptide has an amino acid sequence that does not correspond to the VEGF-VEGFR-2 
sequence and therefore it should show no inhibition. MVF-VEGF P3, VEGF 102-122, 
and MVF-VEGF 102-122 all had similar inhibiting abilities with MVF-VEGF P3 
showing a decrease in binding of the VEGF P3 peptide to the anti-VEGF P3 antibody.  
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Figure 3.8 Anti-VEGF P4 competitive inhibition ELISA.  Plates were coated with 
VEGF P4 peptide and anti-VEGF P4 binding was analyzed directly (A) or in competition 
assay (B) where VEGF peptide mimics were used as inhibitors.
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Figure 3.8 shows the direct (A) and competitive ELISA (B) between VEGF P4 and anti-
VEGF P4 antibodies, which were produced after New Zealand white rabbits were 
immunized three times at three week intervals. The bleed, 6y+3w (three weeks after the 
sixth immunization) was found to have the highest titer readings (Figure 3.8). The 
purified antibodies from the 6y+3w bleed were then added to the 96-well plates that had 
been coated with VEGF P4. The competitive ELISA also used different peptides as 
inhibitors to prevent binding between VEGF P4 and its antibodies. As is expected, the 
irrelevant peptide (IRR) showed no ability to inhibit VEGF P4 binding to its antibody. 
The peptide has an amino acid sequence that does not correspond to the VEGF-VEGFR-2 
sequence and therefore it should show no inhibition. VEGF P4, VEGF102-122, and 
MVF-VEGF 102-122 had differing inhibiting abilities.  
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CHAPTER 4 
 
DISCUSSION 
 
In each competitive ELISA the antibodies with a specific dilution that was based 
on the linear portion of the direct ELISA was used. At the point on the direct ELISA 
where the graph is linear, the dilution at that value is considered an ideal control for 
competitive ELISA using antibodies at that dilution. The results showed that the 
antibodies produced in rabbits after peptide vaccine immunization were able to recognize 
and bind the VEGF protein. The peptides were also able to compete with VEGF for 
binding to the antibodies. In figure 3.3, the direct ELISA showed a gradual change in 
binding as the antibodies were diluted. In the competitive ELISA, the irrelevant peptide 
was not able to inhibit binding while the VEGF 102-122 peptide showed the most effects 
due to its similar structure with the coated protein, allowing for inhibition to occur. MVF-
VEGF P3 showed very little inhibiting ability. VEGF 102-122 showed the most 
inhibition followed by MVF-VEGF 102-122 which are both expected because they share 
exact sequences and conformational structures as the peptide they are competing against 
the antibodies for binding. 
In figure 3.4, the direct ELISA does not decrease as expected. The high binding 
made choosing a dilution for the competitive ELISA, inaccurate. In the competitive 
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ELISA, the irrelevant peptide was not able to inhibit binding while the VEGF P3 peptide 
showed the most effects due to its similar structure with the coated protein, allowing for 
inhibition to occur. MVF-VEGF P3 and MVF-VEGF 102-122 showed very little 
inhibiting ability. The high binding signifies little inhibition by peptides and high binding 
affinity of the antibody to the peptides. This may be due to the inhibiting peptides being 
denatured after numerous thawing and re-freezing which can take its toll on the structural 
integrity of peptides. Each competitive ELISA should show nearly identical binding for 
the wells with no inhibiting peptide. This is because no peptide is competing and is a 
measure of the consistency of the tests. As the inhibiting peptides concentration 
increases, the MVF P3, MVF 102-122, and 102-122 peptides are expected to show 
different inhibiting abilities depending on what peptide is coated on the plate that they are 
competing with the antibodies for the binding region of the peptide.  
In figure 3.5, the direct ELISA showed a gradual change in binding as the 
antibody concentration was diluted. The competitive ELISA, showed little binding 
inhibition in the irrelevant peptide, and a gradual decrease in each of the other peptides 
with VEGF P4 showing the most change due to its similar structure with the coated 
protein, followed by MVF-VEGF P4, allowing for inhibition to occur. VEGF P4 is 
observed to be the best competing peptide for MVF-VEGF P4. The peptide is observed to 
be inhibiting on the antibody-peptide interactions and would be a good candidate for in 
vivo trials. 
Figure 3.6 had a direct ELISA that showed a gradual change in the binding as the 
antibodies were diluted. In the competitive ELISA, the irrelevant peptide was not able to 
inhibit binding while the VEGF 102-122 peptide showed the most change due to its 
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similar structure with the coated protein, allowing for inhibition to occur. No peptide 
showed significant inhibiting abilities or a greater decrease in binding between the VEGF 
102-122 peptide and its antibody should have been observed via the absorbance readings 
decreasing as inhibitor concentration increased. This may be due to degradation of the 
peptide mimics after a number of tests had been conducted with them. The results could 
be clarified with more trials and consistent data that was observed time and time again 
using newly synthesized peptide mimics. 
As seen in figure 3.7, the direct ELISA had decreased binding as the antibodies 
were diluted. The competitive ELISA, showed inhibition in binding when irrelevant 
peptide was competing and a gradual decrease in binding was seen in each of the other 
peptides with the MVF-VEGF P3 peptide showing the most inhibition. It is expected that 
MVF-VEGF P3 has the greatest inhibition. MVF-VEGF 102-122 and VEGF 102-122 
show similar binding inhibition, which is also expected as both peptides have the same B-
cell epitope, which is not cyclized and therefore not a conformational match for the 
VEGF P3, coated on the plate. 
Figure 3.8 has a direct ELISA that showed decreased antibody binding as the 
antibodies were diluted. In the competitive ELISA, the irrelevant peptide was not able to 
inhibit binding while the VEGF 102-122 peptide showed the most inhibition followed by 
MVF-VEGF P4. VEGF 102-122 has a more flexible structure due to it not being 
cyclized. As a result, in vitro tests may yield higher results compared to cyclized peptides 
(VEGF P3 and VEGF P4), but in vivo testing may show differing affinities.  
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CHAPTER 5 
 
CONCLUSION AND CONTINUING RESEARCH 
  
 As more and more research is conducted on cancer and as drug therapies are 
being developed for the prevention of continued tumor growth and metastasis, the 
inhibition of the tumor growth has become a highly studied aspect by most researchers. 
The cost to develop novelty drugs is very expensive as the process includes discovery and 
implementation of the drugs with patents increasing the already taxing cost. Because of 
financial questions, companies and researchers have turned to the idea of peptide use to 
combat tumor growth by inhibiting receptor sites [25]. The focus of the research was on 
the interaction between an over expressed oncoprotein, VEGF, and its receptor site seen 
on tumors where it signaled angiogenesis to begin. 
 The focus of the research was on the efficacy of the VEGF peptide vaccine in 
producing antibodies that can inhibit the interaction between VEGF and VEGFR-2. The 
ELISA tests are effective in showing in vitro that the RI-VEGF peptide sequences can 
inhibit the binding of the anti-VEGF antibodies. This knowledge can be applied to animal 
and eventually human trials. Continued studies of VEGF’s role in angiogenesis are being 
looked at and currently, research is looking at the combination of peptide mimics for 
VEGFR-2 with other peptide mimics for alternative growth mechanisms. The use of 
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synthetic peptide vaccines that target VEGFR-2 is an important component to cancer 
therapy. 
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